Test Price
750 AED✅ Home Collection Available
Breast Metastatic Marker Panel (CA 15‑3, IHC & Fragment Analysis) in UAE | 750 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing. For the serum component (CA 15‑3): VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. For tissue immunohistochemistry (IHC) and fragment analysis: Secure Medical Courier Solid Tissue Specimen Retrieval from your referring hospital or pathology archive. Telephonic Post-Test Clinical Guidance included. Direct Insurance Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This integrated panel combines serum CA 15‑3 (chemiluminescent immunoassay) with comprehensive immunohistochemical profiling of tumour tissue (ER, PR, HER2/neu, Ki‑67) and optional fragment/STR analysis for microsatellite instability. It is designed for oncologists and specialists to detect, monitor, and predict metastatic behaviour in breast cancer patients.
| Feature | Our Test (DHA‑Licensed) | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity; validated against international datasets | Standard ELISA (95‑97% sensitivity) |
| Methodology | Chemiluminescent Immunoassay + IHC + Fragment/STR | Single‑analyte ELISA only |
| Speed | Same‑day CA 15‑3; tissue 5‑7 days | 2‑3 days for CA 15‑3 alone |
| Price | 750 AED (all‑inclusive) | ~500‑600 AED (limited scope) |
| Compliance | ISO 9001:2015 | UAE PDPL | DHA Regulated | Often lacks regulatory oversight |
Physician Insight & Safety Protocols
“A negative CA 15‑3 or unremarkable IHC does not exclude micrometastatic disease; always correlate with clinical examination, imaging, and histopathology. This panel complements, not replaces, a thorough oncological evaluation.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication Advisory
Do not discontinue any prescribed medication (e.g., tamoxifen, aromatase inhibitors) without consulting your supervising physician. Abrupt cessation may adversely affect disease stability.
Exclusion Criteria & Emergency Red Flags
- Active infection at the biopsy site or systemic sepsis – reschedule once resolved.
- Uncontrolled anticoagulant therapy (INR > 3.0) without medical clearance.
- Patients below 18 years require parental consent as per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Seek immediate emergency care if you experience: sudden severe pain, high fever (>38.5°C), heavy bleeding, or purulent discharge from the biopsy site.
Patient FAQ & Clinical Guidance
1. What does the Breast Metastatic Marker Test detect, and how should I prepare?
This panel detects circulating CA 15‑3 protein levels and immunohistochemical expression of breast cancer biomarkers from tumour tissue. No fasting is required for the blood draw. You must provide prior histopathology reports and the exact biopsy site or block location for tissue retrieval.
2. How quickly will I receive my results and who interprets them?
Your CA 15‑3 result is reported the same day (before 6 PM sample cutoff), while tissue immunohistochemistry takes 5‑7 business days. A DHA‑licensed specialist reviews the integrated report, and you receive a complementary telephonic guidance session post‑result.
3. Is home collection available for both blood and tissue samples?
For the blood component, our ISO‑certified cold‑chain mobile phlebotomists visit your home between 8 AM and 11 PM daily. For tissue, a secure medical courier retrieves the archived specimen (FFPE block or slides) from your hospital or clinic. Direct insurance billing verification is available via WhatsApp +971 54 548 8731 before scheduling.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory framework of the Dubai Health Authority (DHA) and complies with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree‑Law No. 4 of 2016 on Medical Liability (patient consent and safety)
Clinical & Logistical Metadata
| Test Name | Breast Metastatic Marker Panel (CA 15‑3, IHC & Fragment Analysis) |
| Price (AED) | 750 AED (all‑inclusive) |
| Turnaround Time | Same day for CA 15‑3; 5‑7 business days for tissue components |
| Sample Type / Matrix | Peripheral blood (serum) for CA 15‑3; Formalin‑fixed paraffin‑embedded (FFPE) tissue block for IHC and fragment analysis |
| Methodology Used | Chemiluminescent Immunoassay (CLIA), Immunohistochemistry (IHC), Fragment/STR analysis |
| ICD‑10‑CM Code | Z85.3, R97.0, C50.919 |
| LOINC Code | 17877‑9 |
| DHA Facility License & Laboratory Address | License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians